|

Belantamab mafodotin 2.5 mg/kg (8 weeks) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • University of Texas Southwestern Medical Center1

Indications

  • AL Amyloidosis1
  • Amyloidosis1
  • Cancer1

Nashville, Tennessee1 trial

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Vanderbilt Ingram Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.